Forum Markets 

$5.05
115
-$0.03-0.59% Thursday 19:59

Statistics

Day High
5.27
Day Low
4.95
52W High
107
52W Low
1.79
Volume
308,500
Avg. Volume
-
Mkt Cap
108.06M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11AugExpected
Q4 2023
Q2 2024
Q1 2026
Next
-228
-152.07
-76.15
-0.22
Expected EPS
-0.26
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-28.36MNet Income

Analyst Ratings

9.00Average Price Target
The highest estimate is 9.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FRMM. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.9B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that could compete with 180 Life Sciences' novel therapeutic approaches.
Editas Medicine
EDIT
Mkt Cap383.65M
Editas Medicine operates in the genome editing space, directly competing with 180 Life Sciences in developing treatments for diseases with unmet medical needs.
Intellia Therapeutics
NTLA
Mkt Cap1.69B
Intellia Therapeutics is another key player in the CRISPR/Cas9 technology sector, potentially competing with 180 Life Sciences in the field of genetic and autoimmune diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap112.92B
Vertex Pharmaceuticals focuses on creating transformative medicines for people with serious diseases, which aligns with 180 Life Sciences' mission, making them competitors.
Regeneron Pharmaceuticals
REGN
Mkt Cap64.18B
Regeneron Pharmaceuticals is known for its innovation in biotechnology, competing with 180 Life Sciences in developing novel therapeutics for various diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap37.76B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with 180 Life Sciences in the development of novel treatments for genetic and other diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.81B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other innovative treatments for rare genetic diseases, competing with 180 Life Sciences in the rare disease space.
Sarepta Therapeutics
SRPT
Mkt Cap1.62B
Sarepta Therapeutics is focused on the discovery and development of RNA-based therapeutics, competing with 180 Life Sciences in the development of innovative treatments for diseases.

About

Operating within the decentralized finance (DeFi) sector, ETHZilla Corp. is a technology firm. Its core mission is to facilitate global connectivity among financial institutions, enterprises, and various organizations by providing secure and readily accessible blockchain transactions, leveraging implementations of the Ethereum Network protocol. Furthermore, the company sustains its efforts in the biotechnology and gaming industries, overseeing their deployment and ongoing advancement. Founded on September 7, 2016, by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard, ETHZilla Corp. is headquartered in Palm Beach, Florida.
Show more...
CEO
Mr. McAndrew Rudisill BA(Econ)
Employees
3
Country
United States
ISIN
US68236V4014

Listings

0 Comments

Share your thoughts

FAQ

What is Forum Markets stock price today?
The current price of FRMM is $5.05 USD — it has decreased by -0.59% in the past 24 hours. Watch Forum Markets stock price performance more closely on the chart.
What is Forum Markets stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Forum Markets stocks are traded under the ticker FRMM.
Is Forum Markets stock price growing?
FRMM stock has fallen by -1.75% compared to the previous week, the month change is a +11.23% rise, over the last year Forum Markets has showed a -41.55% decrease.
What is Forum Markets market cap?
Today Forum Markets has the market capitalization of 108.06M
When is the next Forum Markets earnings date?
Forum Markets is going to release the next earnings report on August 11, 2026.
What were Forum Markets earnings last quarter?
FRMM earnings for the last quarter are -3.64 USD per share, whereas the estimation was -0.22 USD resulting in a -1,554.55% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Forum Markets revenue for the last year?
Forum Markets revenue for the last year amounts to 0 USD.
What is Forum Markets net income for the last year?
FRMM net income for the last year is -28.36M USD.
How many employees does Forum Markets have?
As of June 22, 2026, the company has 3 employees.
In which sector is Forum Markets located?
Forum Markets operates in the Other sector.
When did Forum Markets complete a stock split?
The last stock split for Forum Markets was on October 20, 2025 with a ratio of 1:10.
Where is Forum Markets headquartered?
Forum Markets is headquartered in Palm Beach, United States.